Maternal and Child Health Journal – Volume 21, Issue 1, January 2017

Maternal and Child Health Journal
Volume 21, Issue 1, January 2017
http://link.springer.com/journal/10995/20/12/page/1

Commentary
Enhancing HIV Treatment Access and Outcomes Amongst HIV Infected Children and Adolescents in Resource Limited Settings
Ameena Ebrahim Goga, Yagespari Singh, Michelle Singh, Nobuntu Noveve, Vuyolwethu  Magasana, Trisha Ramraj, Fareed Abdullah, Ashraf H. Coovadia, Sanjana Bhardwaj, Gayle G. Sherman

Abstract
Introduction
Increasing access to HIV-related care and treatment for children aged 0–18 years in resource-limited settings is an urgent global priority. In 2011–2012 the percentage increase in children accessing antiretroviral therapy was approximately half that of adults (11 vs. 21 %). We propose a model for increasing access to, and retention in, paediatric HIV care and treatment in resource-limited settings.

Methods
Following a rapid appraisal of recent literature seven main challenges in paediatric HIV-related care and treatment were identified: (1) lack of regular, integrated, ongoing HIV-related diagnosis; (2) weak facility-based systems for tracking and retention in care; (3) interrupted availability of dried blood spot cards (expiration/stock outs); (4) poor quality control of rapid HIV testing; (5) supply-related gaps at health facility-laboratory interface; (6) poor uptake of HIV testing, possibly relating to a fatalistic belief about HIV infection; (7) community-associated reasons e.g. non-disclosure and weak systems for social support, resulting in poor retention in care.

Results
To increase sustained access to paediatric HIV-related care and treatment, regular updating of Policies, review of inter-sectoral Plans (at facility and community levels) and evaluation of Programme implementation and impact (at national, subnational, facility and community levels) are non-negotiable critical elements. Additionally we recommend the intensified implementation of seven main interventions: (1) update or refresher messaging for health care staff and simple messaging for key staff at early childhood development centres and schools; (2) contact tracing, disclosure and retention monitoring; (3) paying particular attention to infant dried blood spot (DBS) stock control; (4) regular quality assurance of rapid HIV testing procedures; (5) workshops/meetings/dialogues between health facilities and laboratories to resolve transport-related gaps and to facilitate return of results to facilities; (6) community leader and health worker advocacy at creches, schools, religious centres to increase uptake of HIV testing and dispel fatalistic beliefs about HIV; (7) use of mobile communication technology (m-health) and peer/community supporters to maintain contact with patients.

Discussion and Conclusion
We propose that this package of facility, community and family-orientated interventions are needed to change the trajectory of the paediatric HIV epidemic and its associated patterns of morbidity and mortality, thus achieving the double dividend of improving HIV-free survival.

Original Paper
State-Level Immunization Information Systems: Potential for Childhood Immunization Data Linkages
Jill E. Fuller, Emmanuel B. Walter Jr., Nancy Dole, Richard O’Hara, Amy H. Herring, Maureen S. Durkin, Bonny Specker, Betty Wey

Nature – Volume 541 Number 7637 pp259-430 19 January 2017

Nature
Volume 541 Number 7637 pp259-430 19 January 2017
http://www.nature.com/nature/current_issue.html

Editorials
Trump’s vaccine-commission idea is biased and dangerous
Scientists must fight back with the truth about the debunked link between vaccines and autism
Critics call Donald Trump unpredictable. “Who knows what he will do next?” has become a popular rhetorical question in US politics. And yet, quite often his actions are entirely predictable. The difficulty comes in comprehending them.

A prime example is last week’s revelation by environmental lawyer Robert F. Kennedy Jr that president-elect Trump may put together a commission to study “vaccine safety and scientific integrity”. (Trump’s team has countered that there are no definite plans to do so.) Kennedy says he would head the commission; he has in the past argued — unconvincingly — that a preservative in some childhood vaccines is linked to autism spectrum disorder, despite abundant evidence to the contrary.

Trump’s embrace of the tiresome and discredited anti-vaccination movement is no secret. He has tweeted and publicly discussed his concerns that childhood vaccines may be linked to autism. He has previously met with like-minded activists, including Andrew Wakefield, a father of the ‘anti-vaxxer’ crusade who has been barred from practising medicine in the United Kingdom for professional misconduct.

Given the people Trump has chosen to listen to, his suggestion of a Kennedy-headed vaccine commission should be no surprise. But it remains difficult to grasp how someone in his position, with unlimited access to the world’s best resources on vaccine safety, would selectively choose to overlook them all: the studies, the commissions, the scientists who have spent a lifetime studying vaccines. What good is another investigation of speculation already so thoroughly analysed and debunked — unless it is being set up to reach a different conclusion? It is a clear waste of money and effort. Much more frustratingly, it fuels an anti-vaccination movement that puts children and elderly people at risk.

Trump surely knows that there is already a federal commission to evaluate vaccine safety. The US Centers for Disease Control and Prevention (CDC) has an Advisory Committee on Immunization Practices that reports to the government on vaccine safety. Vaccines are also regulated by the US Food and Drug Administration — and often have particularly stringent safety requirements because they are used in healthy children.
There is already ample evidence that vaccines do not elevate the risk of autism. A 2015 study of more than 95,000 children found no association between the measles, mumps and rubella vaccine and an increased risk of autism — even among children with a family history of the disorder (A. Jain et al. J. Am. Med. Assoc. 313, 1534–1540; 2015). As for Kennedy’s argument about vaccine preservatives, the CDC has repeatedly tried — and failed — to find a link between that preservative, called thimerosal, and autism. In 2004, the US Institute of Medicine reported that a review of the literature had also found no such link (see go.nature.com/2jwe4ba). And in the United States, the argument is now moot: thimerosal was removed from most childhood vaccines administered in the country, as a precautionary measure, beginning in 2001. Autism diagnoses continued unabated.

All the evidence shows that it is actually misconceptions about vaccines — such as those promoted by Trump — that cause serious harm. The United States has already experienced a series of outbreaks of preventable diseases. In 2014, measles affected 667 people in the country, primarily those who were unvaccinated. The outbreaks are expensive, too: in 2011, it cost public-health institutions up to US$5.3 million to cope with 16 measles outbreaks that made 107 people ill.

If Trump moves ahead with his vaccine commission, he will give a sense of legitimacy to opponents of childhood vaccination. This could undercut efforts in some states, such as Texas and Michigan, to strengthen vaccination requirements for schoolchildren.

In the wake of the news about the commission, the American Medical Association moved to reassert the safety of vaccines. The American Academy of Pediatrics said that it would welcome the chance to discuss vaccine safety with Trump.

Scientists, medics and commentators who have fought vaccine disinformation in the past must take a deep breath and return to the fray. There is no need to wait for this commission to be announced officially. There is no need to wait until it issues its findings. There is no cause to be surprised if it shows little regard for science — or even if it targets scientists who speak out in favour of vaccination. Those who claim a link between vaccines and autism can do so only by discrediting the scientific evidence and, often, the scientists who gathered it. Kennedy’s reference to investigating vaccine safety “and scientific integrity” provides ample warning of what is to come. Scientists should get their retaliation in first. Lives are at stake.

Nature – Volume 541 Number 7637 pp259-430 19 January 2017

Nature
Volume 541 Number 7637 pp259-430 19 January 2017
http://www.nature.com/nature/current_issue.html

Editorials
Replication studies offer much more than technical details
They demonstrate the practice of science at its best.
Purists will tell you that science is about what scientists don’t know, which is true but not much of a basis on which to develop new cancer drugs. Hence the importance of knowledge: how crucial this mutation or that cell-surface receptor really is to cancer growth. These are the findings that launch companies and clinical trials — provided, of course, that they have been published in research papers in peer-reviewed journals.

As we report in a News story this week, a systematic effort to check some of these findings by repeating an initial five published cancer studies has reported that none could be completely reproduced. The significance of this divergence — how the specific experiments were selected and what the results mean for the broader agenda of reproducibility in research — is already hotly contested.

Perhaps the most influential aspect of the exercise, called the Reproducibility Project: Cancer Biology, has nothing to do with those arguments. It lies beneath the surface, in the peer reviews of the project teams’ replication plans, which were published before the studies began. These reviews can be read as part of the editorial decision letters linked to each replication plan, or ‘registered report’ (see go.nature.com/2jte08a)…

PLOS Currents: Disasters

PLOS Currents: Disasters
http://currents.plos.org/disasters/
[Accessed 21 January 2017]

Brief Report
The Solidarity and Health Neutrality of Physicians in War & Peace
January 20, 2017 ·
The wars in the Middle East have led to unprecedented threats and attacks on patients, healthcare workers, and purposeful targeting of hospitals and medical facilities. It is crucial that every healthcare provider, both civilian and military, on either side of the conflict become aware of the unique and inherent protections afforded to them under International Humanitarian Law. However, these protections come with obligations. Whereas Governments must guarantee these protections, when violated, medical providers have equal duty and obligations under the Law to ensure that they will neither commit nor assist in these violations nor take part in any act of hostility. Healthcare providers must not allow any inhuman or degrading treatment of which they are aware and must report such actions to the appropriate authorities. Failure to do so leads to risks of moral, ethical and legal consequences as well as penalties for their actions and inactions. There must be immediate recognition by all parties of the neutrality of health care workers and their rights and responsibilities to care for any sick and injured patient, regardless of their nationality, race, religion, or political point of view.

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 21 January 2017]

Research Article
Childhood Vaccine Acceptance and Refusal among Warao Amerindian Caregivers in Venezuela; A Qualitative Approach
Jochem Burghouts, Berenice Del Nogal, Angimar Uriepero, Peter W. M. Hermans, Jacobus H. de Waard, Lilly M. Verhagen
Research Article | published 20 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0170227
Abstract

Objectives
Acceptance of childhood vaccination varies between societies, affecting worldwide vaccination coverage. Low coverage rates are common in indigenous populations where parents often choose not to vaccinate their children. We aimed to gain insight into reasons for vaccine acceptance or rejection among Warao Amerindians in Venezuela.

Methods
Based on records of vaccine acceptance or refusal, in-depth interviews with 20 vaccine-accepting and 11 vaccine-declining caregivers were performed. Parents’ attitudes were explored using a qualitative approach.

Results
Although Warao caregivers were generally in favor of vaccination, fear of side effects and the idea that young and sick children are too vulnerable to be vaccinated negatively affected vaccine acceptance. The importance assigned to side effects was related to the perception that these resembled symptoms/diseases of another origin and could thus harm the child. Religious beliefs or traditional healers did not influence the decision-making process.

Conclusions
Parental vaccine acceptance requires educational programs on the preventive nature of vaccines in relation to local beliefs about health and disease. Attention needs to be directed at population-specific concerns, including explanation on the nature of and therapeutic options for side effects.

Do Thai Physicians Recommend Seasonal Influenza Vaccines to Pregnant Women? A Cross-Sectional Survey of Physicians’ Perspectives and Practices in Thailand
Prabda Praphasiri, Darunee Ditsungneon, Adena Greenbaum, Fatimah S. Dawood, Pornsak Yoocharoen, Deborah M. Stone, Sonja J. Olsen, Kim A. Lindblade, Charung Muangchana
Research Article | published 18 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0169221

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 21 January 2017]

A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines
Thomas Richardson, Andrew McDonald Johnston, Heather Draper
Research Article | published 17 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0168975
Abstract
Background
Objective: To determine to what extent each trial met criteria specified in three research frameworks for ethical trial conduct.
Design: Systematic review and narrative analysis

Methods and findings
Data sources: MEDBASE and EMBASE databases were searched using a specific search strategy. The Cochrane database for systematic reviews, the PROSPERO database and trial registries were examined. A grey literature search and citation search were also carried out.
Eligibility criteria for selecting studies: Studies were included where the intervention was being used to treat Ebola in human subjects regardless of study design, comparator or outcome measured. Studies were eligible if they had taken place after the 21st March 2014. Unpublished as well as published studies were included.
Included studies: Sixteen studies were included in the data synthesis. Data was extracted on study characteristics as well as any information relating to ten ethical areas of interest specified in the three research frameworks for ethical trial conduct and an additional criterion of whether the study received ethics approval from a research ethics committee.
Synthesis of results: Eight studies were judged to fully comply with all eleven criteria. The other eight studies all had at least one criteria where there was not enough information available to draw any conclusions. In two studies there were ethical concerns regarding the information provided in relation to at least one ethical criteria.
Description of the effect: One study did not receive ethical approval as the authors argued that treating approximately one hundred patients consecutively for compassionate reasons did not constitute a clinical trial. Furthermore, after the patients were treated, physicians in Sierra Leone did not release reports of treatment results and so study conclusions had to be made based on unpublished observations. In another study the risk-benefit ratio of the trial drug does not appear to be favourable and the pre-trial evidence base for its effectiveness against Ebola is speculative.

Conclusions
Some limited and appropriate deviation from standard research expectations in disaster situations is increasingly accepted. However, this is not an excuse for poor ethics oversight and international regulations are in place which should not be ignored. New guidelines are needed that better define the boundaries between using medicines for compassionate use and conducting a clinical trial. Greater support should be offered for local research ethics committees in affected areas so that they can provide robust ethical review. Further systematic reviews should be carried out in epidemics of any novel infectious diseases to assess if comparable findings arise.

Science – 20 January 2017 Vol 355, Issue 6322

Science
20 January 2017 Vol 355, Issue 6322
http://www.sciencemag.org/current.dtl

Feature
Taming rabies
By Erik Stokstad
Science20 Jan 2017 : 238-242 Full Access
The best way to stop people from dying of rabies is to protect dogs. Can that strategy work in the world’s poorest countries?

Summary
An estimated 59,000 people die from rabies around the world every year. Their horrible suffering—including convulsions, terror, and aggression—and the fact that many victims are children led the World Health Organization and others to announce a goal to eliminate rabies deaths worldwide by 2030. The plan calls for cheaper and faster treatment for people. But its long-term bet is on vaccinating domestic dogs, which cause more than 99% of infections. The challenges are enormous in sub-Saharan Africa, where poor countries can hardly pay for millions of dogs to be vaccinated, and their governments often have trouble organizing vaccination campaigns across vast rural areas. In pilot projects underway in Tanzania, Kenya, and a few other African countries, scientists are testing strategies for reaching and vaccinating dogs more efficiently and quantifying the economic benefits of potentially expensive national campaigns. For Africa as a whole, rabies elimination might cost between $800 million to $1.55 billion. The price could come down, however, from dog vaccine banks, for example, and other ways to make vaccines cheaper and more easily distributed.

Perspectives
Technology beats corruption
By Rema Hanna
Science20 Jan 2017 : 244-245 Full Access
Biometric smart cards help to reduce corruption in cash transfer programs in India

Summary
More than 1.9 billion individuals in the developing world benefit from social safety net programs: noncontributory transfer programs that distribute cash or basic in-kind products to the poor. But despite their importance, high levels of corruption often stifle the effectiveness of these programs. If cash transfer programs are particularly prone to graft, then in-kind programs should be preferred in practice. In a recent paper, Muralidharan et al. report evidence to the contrary by showing that use of a modern banking technology—biometric smart cards—can help to drastically reduce corruption in cash transfer programs (1).

Review
Human tissues in a dish: The research and ethical implications of organoid technology
By Annelien L. Bredenoord, Hans Clevers, Juergen A. Knoblich
Science20 Jan 2017
Abstract
Growing functional human tissues and organs would provide much needed material for regeneration and repair. New technologies are taking us in that direction. In addition to their use in regenerative medicine, stem cells that grow and morph into organ-like structures known as organoids can be used in drug development and toxicology testing. The potential developments and possibilities are numerous and affect not only biomedicine but also areas of ongoing ethical debate, such as animal experimentation, research on human embryos and fetuses, ethics review, and patient consent. Bredenoord et al. review how organoids affect existing ethical debates and how they raise novel ethical dilemmas and professional responsibilities.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Brief report
Interest in an Ebola vaccine among a U.S. national sample during the height of the 2014–2016 Ebola outbreak in West Africa
Pages 508-512
Julia E. Painter, Ralph J. DiClemente, Michael E. von Fricken

Abstract
To better understand the association between Ebola-related attitudes and interest in receiving an Ebola virus vaccine, a survey was administered to a U.S. national sample using GfK’s KnowledgePanel®. Among participants (N = 1417), 34.1% expressed interest in an Ebola vaccine for themselves. In the subset of participants with children aged 0–17 (N = 410), 38.1% expressed interest in an Ebola vaccine for their child. In multivariable analyses, vaccine interest for oneself was associated with perceived susceptibility to Ebola (p = 0.009), beliefs that the U.S. government should spend money to control Ebola (p = 0.002), and beliefs Ebola posed a national threat (p = 0.007). Vaccine interest for one’s child was associated with perceived severity of Ebola (p = 0.018) and beliefs that the U.S. government should spend money to control Ebola (p = 0.003). Findings highlight the influence of personal and national threat beliefs on vaccine interest. Understanding the impact of threat beliefs may benefit vaccine campaign development during future pandemic threats

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
Review Article
Pages 513-520
Alexander Domnich, Lucia Arata, Daniela Amicizia, Joan Puig-Barberà, Roberto Gasparini, Donatella Panatto
Abstract

Background
In the elderly, traditional influenza inactivated vaccines are often only modestly immunogenic, owing to immunosenescence. Given that adjuvantation is a means of enhancing the immune response, the trivalent inactivated vaccine adjuvanted with MF59 (MF59-TIV) was specifically designed to overcome this problem. Considering that, for ethical reasons, the absolute effectiveness of an influenza vaccine in the elderly cannot be demonstrated in placebo-controlled studies, the present study aimed to assess the effectiveness of MF59-TIV in preventing influenza-related outcomes in the elderly.

Methods
We conducted a systematic review of observational studies aimed at evaluating the effectiveness of MF59-TIV against influenza-related outcomes. Results of single studies were pooled whenever possible.

Results
Of the 1993 papers screened, 11 (6 case-control, 3 cohort and 2 prospective case-control) studies were identified. Hospitalization due to pneumonia/influenza and laboratory-confirmed influenza were reported in more than one study, while other outcomes (influenza-like illness, cardio- and cerebrovascular accidents) were investigated only by one study each. Pooled analysis of four case-control studies showed an adjusted MF59-TIV effectiveness of 51% (95% CI: 39–61%) against hospitalizations for pneumonia/influenza among community-dwelling seniors. Pooled results of the adjusted vaccine effectiveness against laboratory-confirmed influenza were also high (60.1%), although the 95% CI passed through zero (−1.3 to 84.3%). Other single community-based studies showed very high effectiveness of MF59-TIV in preventing hospitalizations for acute coronary [87% (95% CI: 35–97%)] and cerebrovascular [93% (95% CI: 52–99%)] events. MF59-TIV proved highly effective [94% (95% CI: 47–100%] in reducing influenza-like illness among institutionalized elderly. Furthermore, MF59-TIV displayed greater efficacy than non-adjuvanted vaccines in preventing hospitalizations due to pneumonia/influenza [adjusted risk ratio 0.75 (95% CI: 0.57–0.98)] and laboratory-confirmed influenza [adjusted odds ratio 0.37 (0.14–0.96)].

Conclusions
Our results suggest that MF59-TIV is effective in reducing several influenza-related outcomes among the elderly, especially hospitalizations due to influenza-related complications.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies
Review Article
Pages 521-528
Dominik Mertz, Johanna Geraci, Judi Winkup, Bradford D. Gessner, Justin R. Ortiz, Mark Loeb
Abstract

Background
Pregnancy is considered to be an important risk factor for severe complications following influenza virus infection. As a consequence, WHO recommendations prioritize pregnant women over other risk groups for influenza vaccination. However, the risk associated with pregnancy has not been systematically quantified.

Purpose
Systematic review and meta-analysis of observational studies that reported on pregnancy as a risk factor for severe outcomes from influenza virus infection.

Data source
MEDLINE, EMBASE, CINAHL, and CENTRAL up to April 2014.

Data selection
Studies reporting on outcomes in pregnant women with influenza in comparison to non-pregnant patients with influenza. Outcomes included community-acquired pneumonia, hospitalization, admission to intensive care units (ICU), ventilatory support, and death.

Data extraction
Two reviewers conducted independent screening and data extraction. A random effects model was used to obtain risk estimates. Ecological studies were summarized descriptively.

Data synthesis
A total of 142 non-ecological and 10 ecological studies were included. The majority of studies (n = 136, 95.8%) were conducted during the 2009 influenza A (pH1N1) pandemic. There was a higher risk for hospitalization in pregnant versus non-pregnant patients infected with influenza (odds ratio [OR] 2.44, 95% CI 1.22–4.87), but no significant difference in mortality (OR 1.04, 95% CI 0.81–1.33) or other outcomes. Ecologic studies confirmed the association between hospitalization risk and pregnancy and 4 of 7 studies reported higher mortality rates in pregnant women.

Limitations
No studies were identified in which follow-up began prior to contact with the healthcare system and lack of adjustment for confounding factors.

Conclusions
We found that influenza during pregnancy resulted in a higher risk of hospital admission than influenza infection in non-pregnant individuals, but that the risk of mortality following influenza was similar in both pregnant and non-pregnant individuals.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone
Original Research Article
Pages 544-551
A. Camacho, R.M. Eggo, N. Goeyvaerts, A. Vandebosch, R. Mogg, S. Funk, A.J. Kucharski, C.H. Watson, T. Vangeneugden, W.J. Edmunds
Abstract

Background
Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013–16 Ebola virus disease (EVD) epidemic in West Africa. Mathematical models can provide forecasts of expected incidence through time and can account for both vaccine efficacy in participants and effectiveness in populations. Determining expected disease incidence was critical to calculating power and determining trial sample size.

Methods
In real-time, we fitted, forecasted, and simulated a proposed phase 3 cluster-randomized vaccine trial for a prime-boost EVD vaccine in three candidate regions in Sierra Leone. The aim was to forecast trial feasibility in these areas through time and guide study design planning.

Results
EVD incidence was highly variable during the epidemic, especially in the declining phase. Delays in trial start date were expected to greatly reduce the ability to discern an effect, particularly as a trial with an effective vaccine would cause the epidemic to go extinct more quickly in the vaccine arm. Real-time updates of the model allowed decision-makers to determine how trial feasibility changed with time.

Conclusions
This analysis was useful for vaccine trial planning because we simulated effectiveness as well as efficacy, which is possible with a dynamic transmission model. It contributed to decisions on choice of trial location and feasibility of the trial. Transmission models should be utilised as early as possible in the design process to provide mechanistic estimates of expected incidence, with which decisions about sample size, location, timing, and feasibility can be determined.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Knowledge and recommendation regarding routine childhood vaccinations among pediatric healthcare providers in Israel
Original Research Article
Pages 633-638
Rana Shibli, Rivka Shemer, Liat Lerner-Geva, Shmuel Rishpon
Abstract

Background
A recommendation by pediatric healthcare providers (HCPs) is a major factor influencing parents’ decision to vaccinate their children. Consequently, it is important to understand the motives behind the HCPs’ recommendations to vaccinate children according to the routine immunization program.

Objectives
To study the association of pediatric HCPs’ knowledge about and attitudes towards childhood vaccinations and of their professional and demographic characteristics, with two variables: 1. Their recommendations to parents regarding adherence to the routine immunization program. 2. Their choices concerning routine immunization of their own children.

Study design and settings
We conducted a cross-sectional study of pediatric nurses and physicians working at Mother-Child Health Clinics (MCHCs) in Haifa and Tel-Aviv districts and at a hospital in Hadera City, Israel.

Methods
A structured, anonymous self-administered questionnaire was used.

Results
The overall response rate was 60%, totaling 218 participants. 92% of whom were nurses. Misconceptions related to vaccine safety were found among a high percentage of the participants. The HCPs knowledge level was associated with the HCPs vaccinating their own children according to the recommended immunization program (OR=1.32; CI95% 1.06–1.64), but not with their recommendation to parents to adhere to the program. No association was found between attitudes and these variables. Workplace (MCHCs versus hospital) correlated with the above mentioned two dependent variables (OR=1.89; CI95% 1.21–2.97 and OR=2.42; CI95% 1.73–3.4, respectively).

Conclusions
Amplifying the knowledge of HCPs and addressing their concern about vaccinations can improve their adherence to the routine immunization program regarding their own children. This may lead to better adherence of other parents who are frequently interested in the HCPs’ behavior and consider them as a role model. In general, there is a need to emphasize the HCP’s responsibility for the successful implementation of the immunization program in the community and at hospitals.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Primary care physicians’ perspective on financial issues and adult immunization in the Era of the Affordable Care Act
Original Research Article
Pages 647-654
Laura P. Hurley, Megan C. Lindley, Mandy A. Allison, Lori A. Crane, Michaela Brtnikova, Brenda L. Beaty, Megan Snow, Carolyn B. Bridges, Allison Kempe

Abstract
Background
Financial barriers to adult vaccination are poorly understood. Our objectives were to assess among general internists (GIM) and family physicians (FP) shortly after Affordable Care Act (ACA) implementation: (1) proportion of adult patients deferring or refusing vaccines because of cost and frequency of physicians not recommending vaccines for financial reasons; (2) satisfaction with reimbursement for vaccine purchase and administration by payer type; (3) knowledge of Medicare coverage of vaccines; and (4) awareness of vaccine-specific provisions of the ACA.

Methods
We administered an Internet and mail survey from June to October 2013 to national networks of 438 GIMs and 401 FPs.

Results
Response rates were 72% (317/438) for GIM and 59% (236/401) for FP. Among physicians who routinely recommended vaccines, up to 24% of GIM and 30% of FP reported adult patients defer or refuse certain vaccines for financial reasons most of the time. Physicians reported not recommending vaccines because they thought the patient’s insurance would not cover it (35%) or the patient could be vaccinated more affordably elsewhere (38%). Among physicians who saw patients with this insurance, dissatisfaction (‘very dissatisfied’) was highest for payments received from Medicaid (16% vaccine purchase, 14% vaccine administration) and Medicare Part B (11% vaccine purchase, 11% vaccine administration). Depending on the vaccine, 36–71% reported not knowing how Medicare covered the vaccine. Thirty-seven percent were ‘not at all aware’ and 19% were ‘a little aware’ of vaccine-specific provisions of the ACA.

Conclusions
Patients are refusing and physicians are not recommending adult vaccinations for financial reasons. Increased knowledge of private and public insurance coverage for adult vaccinations might position physicians to be more likely to recommend vaccines and better enable them to refer patients to other vaccine providers when a particular vaccine or vaccines are not offered in the practice.

Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted
Original Research Article
Pages 680-686
Sara L. Thomas, Jemma L. Walker, Justin Fenty, Katherine E. Atkins, Alex J. Elliot, Helen E. Hughes, Julia Stowe, Shamez Ladhani, Nick J. Andrews
Abstract
Background
Introduction of infant oral rotavirus vaccination in the UK in July 2013 has resulted in decreased hospitalisations and Emergency Department (ED) visits for acute gastroenteritis (AGE), for both adults and children. We investigated reductions in AGE incidence seen in primary care in the two years after vaccine introduction, and estimated the healthcare costs averted across healthcare settings in the first year of the vaccination programme.
Methods
We used primary care data from the Clinical Practice Research Datalink and age-stratified time-series analyses to derive adjusted incidence rate ratios (IRRa) for AGE in the first two years of the post-vaccination era (July 2013-April 2015) compared to the pre-vaccination era (July 2008-June 2013). We estimated cases averted among children aged Results
In general practice, AGE rates in infants (the target group for vaccination) decreased by 15% overall after vaccine introduction (IRRa = 0.85; 95%CI=0.76–0.95), and by 41% in the months of historically high rotavirus circulation (IRRa=0.59; 95%CI=0.53–0.66). Rates also decreased in other young children and to a lesser degree in older individuals, indicating herd immunity. Across all three settings (general practice, EDs, and hospitalisations) an estimated 87,376 (95% prediction interval: 62,588–113,561) AGE visits by children aged Conclusions
The marked decreases in the general practice AGE burden after rotavirus vaccine introduction mirror decreases seen in other UK healthcare settings. Overall, these decreases are associated with substantial averted healthcare costs.

Vaccine – Volume 35, Issue 3, Pages 411-502 (11 January 2017)

Vaccine
Volume 35, Issue 3, Pages 411-502 (11 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/3

Letter to the Editor
Ensuring access to oral cholera vaccine to those who need them most
Francisco J. Luquero, Anne Ballard, David A. Sack
[No abstract]

Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan
Original Research Article
Pages 435-442
Lisa M. Gargano, Rana Hajjeh, Susan T. Cookson
Abstract
By September 2013, war between Sudan and South Sudan resulted in >70,000 Sudanese refugees and high pneumonia incidence among the 20,000 refugees in Yida camp, South Sudan. Using Médecins Sans Frontières (MSF)-provided data and modifying our decision-tree models, we estimated if administering Haemophilus influenzae type b (Hib)-containing (pentavalent vaccine, also with diphtheria pertussis and tetanus [DPT] and hepatitis B) and pneumococcal conjugate (PCV) vaccines were cost-effective against hospitalized pneumonia. Among children

Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study
Original Research Article
Pages 443-451
Christel Hoest, Jessica C. Seidman, Gwenyth Lee, James A Platts-Mills, Asad Ali, Maribel Paredes Olortegui, Pascal Bessong, Ram Chandyo, Sudhir Babji, Venkata Raghava Mohan, Dinesh Mondal, Mustafa Mahfuz, Estomih R Mduma, Emanuel Nyathi, Claudia Abreu, Mark A. Miller, William Pan, Carl J. Mason, Stacey L. Knobler, the MAL-ED Network Investigators
Abstract
Background
Launched in 1974, the Expanded Program on Immunization (EPI) is estimated to prevent two-three million deaths annually from polio, diphtheria, tuberculosis, pertussis, measles, and tetanus. Additional lives could be saved through better understanding what influences adherence to the EPI schedule in specific settings.
Methods
The Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) study followed cohorts in eight sites in South Asia, Africa, and South America and monitored vaccine receipt over the first two years of life for the children enrolled in the study. Vaccination histories were obtained monthly from vaccination cards, local clinic records and/or caregiver reports. Vaccination histories were compared against the prescribed EPI schedules for each country, and coverage rates were examined in relation to the timing of vaccination. The influence of socioeconomic factors on vaccine timing and coverage was also considered.
Results
Coverage rates for EPI vaccines varied between sites and by type of vaccine; overall, coverage was highest in the Nepal and Bangladesh sites and lowest in the Tanzania and Brazil sites. Bacillus Calmette-Guérin coverage was high across all sites, 87–100%, whereas measles vaccination rates ranged widely, 73–100%. Significant delays between the scheduled administration age and actual vaccination date were present in all sites, especially for measles vaccine where less than 40% were administered on schedule. A range of socioeconomic factors were significantly associated with vaccination status in study children but these results were largely site-specific.
Conclusions
Our findings highlight the need to improve measles vaccination rates and reduce delayed vaccination to achieve EPI targets related to the establishment of herd immunity and reduction in disease transmission.
Special Section: Immunology and vaccinology of respiratory syncytial virus infections (Guest Editors: D. Altmann and C. Chiu)

Vaccines — Open Access Journal

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 21 January 2017)

A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant
Vaccines 2017, 5(1), 3; doi:10.3390/vaccines5010003 – 19 January 2017
by Janina Jiang, Guangchao Liu, Valerie A. Kickhoefer, Leonard H. Rome, Lin-Xi Li, Stephen J. McSorley and Kathleen A. Kelly
Abstract
Chlamydia trachomatis genital infection is the most common sexually transmitted bacterial disease, causing a significant burden to females due to reproductive dysfunction. Intensive screening and antibiotic treatment are unable to completely prevent female reproductive dysfunction, thus, efforts have become focused on developing a vaccine. A major impediment is identifying a safe and effective adjuvant which induces cluster of differentiation 4 (CD4) cells with attributes capable of halting genital infection and inflammation. Previously, we described a natural nanocapsule called the vault which was engineered to contain major outer membrane protein (MOMP) and was an effective vaccine which significantly reduced early infection and favored development of a cellular immune response in a mouse model. In the current study, we used another chlamydial antigen, a polymorphic membrane protein G-1 (PmpG) peptide, to track antigen-specific cells and evaluate, in depth, the vault vaccine for its protective capacity in the absence of an added adjuvant. We found PmpG-vault immunized mice significantly reduced the genital bacterial burden and histopathologic parameters of inflammation following a C. muridarum challenge. Immunization boosted antigen-specific CD4 cells with a multiple cytokine secretion pattern and reduced the number of inflammatory cells in the genital tract making the vault vaccine platform safe and effective for chlamydial genital infection. We conclude that vaccination with a Chlamydia-vault vaccine boosts antigen-specific immunities that are effective at eradicating infection and preventing reproductive tract inflammation.

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Journal of Nursing Education and Practice
Online Published: January 15, 2017
Predictors of Human Papillomavirus Vaccine uptake or intent among parents of preadolescents and adolescents
Kimberlee Dayal, Sarah Robinson, Jessica Schoening, Mary Catherine Smith, Son Chae Kim
ABSTRACT
Aim: The aim of this study was to examine predictors of human papillomavirus (HPV) vaccine uptake or intent among parents of pre-adolescents and adolescents.
Methods: A cross-sectional descriptive study was conducted among parents of girls aged 9 to 18 years, visiting two primary care clinics in central Texas from September to November 2015. Pearson’s product-moment correlation procedures and path analyses based on Health Belief Model were performed.
Results: Path analysis showed that provider recommendation for HPV vaccination (Beta=-0.37; p < .001) and perceived HPV vaccine harm (Beta=-0.48; p < .001) had statistically significant direct effects on HPV vaccine uptake or intent. The perceived HPV vaccine effectiveness was directly influenced by HPV knowledge (Beta=-0.39; p < .001), empowerment in parent-provider
relationships (Beta=-0.30; p = .006) and parental college education (Beta=-0.23; p = .039).
Conclusions: Together with parental empowerment fostering an equal partnership with providers, targeted education to improve parental HPV knowledge may convince them of the HPV vaccine effectiveness. This, in turn, may help them put the perceived HPV vaccine harm in proper perspective and allow them to make informed decisions regarding the timely HPV vaccination of their children. Because provider recommendation is one of the most important contributing factors for HPV vaccine uptake or intent, parental education and recommendations from nurses will help reduce the knowledge gaps and empower parents to make the timely decisions to vaccinate their children.

Health Education Research
(2017) cyw055 DOI: https://doi.org/10.1093/her/cyw055
Hispanic mothers’ beliefs regarding HPV vaccine series completion in their adolescent daughters
AM Roncancio, KK Ward, CC Carmack, BT Muñoz… – 2017
Abstract
Rates of human papillomavirus (HPV) vaccine series completion among adolescent Hispanic females in Texas in 2014 (∼39%) lag behind the Healthy People 2020 goal (80%). This qualitative study identifies Hispanic mothers’ salient behavioral, normative and control beliefs regarding having their adolescent daughters complete the vaccine series. Thirty-two mothers of girls (aged 11–17) that had received at least one dose of the HPV vaccine, completed in-depth interviews. Six girls had received one dose of the HPV vaccine, 10 girls had received two doses, and 16 girls had received all three doses. The questions elicited salient: (i) experiential and instrumental attitudes (behavioral beliefs); (ii) supporters and non-supporters (normative beliefs) and (iii) facilitators and barriers (control beliefs). Directed content analysis was employed to select the most salient beliefs. Mothers: (i) expressed salient positive feelings (e.g. good, secure, happy and satisfied); (ii) believed that completing the series resulted in positive effects (e.g. protection, prevention); (iii) believed that the main supporters were themselves, their daughter’s father and doctor with some of their friends not supporting series completion and (iv) believed that vaccine affordability, information, transportation, ease of scheduling and keeping vaccination appointments and taking their daughter’s immunization card to appointments were facilitators. This study represents the first step in building theory-based framework of vaccine series completion for this population. The beliefs identified provide guidance for health care providers and intervention developers.

Papillomavirus Research
Available online 17 January 2017
In Press, Accepted Manuscript
Reasons for Acceptance or Refusal of Human Papillomavirus Vaccine in a California Pediatric Practice
B Brown, MI Gabra, H Pellman
Abstract
Despite the effectiveness and availability of the Human Papillomavirus (HPV) vaccine, HPV remains the most common sexually transmitted infection in the United States and has the lowest initiation rate of any routinely recommended teen vaccine. In January 2015, we surveyed parents at a Southern California pediatric private practice about reasons they accept or refuse HPV vaccine for their children. Of the 200 consecutive parents that had HPV vaccine initiation recommended for their child, 123 (61.5%) children were male and 38.5% were female. The overall age range of children was 10–17 years (median 12 years). Of the 164 (82.0%) who accepted the vaccine, a higher percentage were male (88.6% vs 71.4%, p=0.001). The most common reasons for accepting was strength of provider recommendation (84.2%) and available information (63.4%). The most common (55.6%) reason for refusing was wanting to learn more about the vaccine. These results further support the importance of both the strength of physician recommendation and improving public education about the vaccine.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 21 January 2017
The Shadow Network of Anti-Vax Doctors
Both mainstream and alternative doctors help patients avoid or delay vaccines. Trump’s rhetoric might empower them further.
Jan 18, 2017
Olga Khazan
… Brandeis is one of a sizable number of doctors who allow their patients to avoid or delay vaccines if they are concerned about their health effects. It’s unknown how many of these physicians there are, but dozens of names—some even organized by state—come up on earthy mommy blogs and other web communities. “We are hoping to find a pediatrician/pediatric group in the … area who is an MD, but open-minded to alternative medicine, as well as less aggressive vaccination schedules,” wrote one California parent on the Berkeley Parents Network in December.
These doctors—and patients who seek them out—could be emboldened if President-elect Donald Trump goes through with the appointment of Robert F. Kennedy, an environmental activist and vocal vaccine skeptic, to lead a commission “on vaccine safety and scientific integrity,” as was reported last week. Trump met with Kennedy in Trump Tower on January 10, and Kennedy later told his environmental-group colleagues that he would be taking a leave to chair the vaccine commission. (Trump’s team said later that no decision had been made yet.)…

Forbes
http://www.forbes.com/
Accessed 21 January 2017
Letting Seriously Ill Patients Try Drugs Whose Safety, Efficacy Hasn’t Been Proven Could Be Deadly
Rita Rubin, Contributor
One potential candidate for Food and Drug Administration commissioner has supported the idea of allowing drugs on the market as long as they’re safe but before they’ve been proven to be effective. But a new FDA report lists 22 examples of therapies and vaccines whose early promise didn’t pan out.

Huffington Post
http://www.huffingtonpost.com/
Accessed 21 January 2017
Americans Aren’t With Donald Trump On Vaccines
Public health experts and the general public think the president-elect is wrong that shots are unsafe.
19 January 2017
President-elect Donald Trump’s skepticism about the safety of childhood vaccines contrasts not only with the scientific consensus, but also with the opinions of Americans ― fewer than one-quarter of whom think immunization should be a matter of personal choice.
By a more than 2-1 margin, 54 percent to 26 percent, Americans say that the science supporting the safety of childhood vaccination is “indisputable,” rather than something that requires future debate, a new HuffPost/YouGov survey finds, although partisan divides on the issue are widening.
Two-thirds of Americans say that the issue of vaccinating children is a matter of public health, with just 24 percent considering it a matter of personal choice. A 56 percent majority of those polled say they have at least a fair amount of trust in the government to set vaccination policies.
Among public health experts, there’s little disagreement that immunization is safe and effective and one of the greatest public health achievements in modern times…

New York Times
http://www.nytimes.com/
Accessed 21 January 2017
How the Response to Zika Failed Millions
16 January 2017

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 21 January 2017
Gates Foundation Joins Fight Against Epidemics
Jan. 18, 2017 5:59 pm ET

Washington Post
http://www.washingtonpost.com/
Accessed 21 January 2017
Researchers struggle to replicate 5 influential cancer experiments from top labs
Experiments should be reproducible, but most of these weren’t, a research team finds. The original scientists criticize the new results.
Joel Achenbach and Laurie McGinley | National/health-science | Jan 18, 2017

Vaccines and Global Health: The Week in Review 14 January 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: vaccines-and-global-health_the-week-in-review_14-january-2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives

140th session of the Executive Board
23 January–1 February 2017, Geneva
Main Documents [Selected]
EB140/7
Health emergencies
WHO response in severe, large-scale emergencies

EB140/9
Research and development for potentially epidemic diseases
A blueprint for research and development preparedness and rapid research response

EB140/13
Poliomyelitis

EB140/14
Implementation of the International Health Regulations (2005)
Draft global implementation plan

EB140/15
Implementation of the International Health Regulations (2005)
Public health implications of the implementation of the Nagoya Protocol

EB140/16
Review of the Pandemic Influenza Preparedness Framework

EB140/25
Global vaccine action plan
[Excerpt]
ANNEX
A SUMMARY OF THE 2016 ASSESSMENT REPORT OF THE GLOBAL VACCINE ACTION PLAN BY THE STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION [1]
1. At the midpoint of the Global Vaccine Action Plan, or GVAP (2012–2020), the Strategic Advisory Group of Experts on Immunization (SAGE) remains gravely concerned that progress toward the goals to eradicate polio, eliminate measles and rubella, eliminate maternal and neonatal tetanus, and increase equitable access to life saving vaccines is too slow.

2. Despite improvements in individual countries and a strong global rate of new vaccine introduction, global average immunization coverage has increased by only 1% since 2010.

3. In 2015, 68 countries fell short of the target to achieve at least 90% national coverage with the third dose of diphtheria-tetanus-pertussis vaccine. Not only that, 26 countries reported no change in coverage levels and 25 countries reported a net decrease in coverage since 2010.

4. The 16 countries that have made measurable progress since 2010 are to be commended for reaching more people, especially vulnerable and marginalized members of society with immunization. Some of the countries with the highest numbers of unvaccinated people have made the most progress, including the Democratic Republic of the Congo, Ethiopia and India, and even though coverage targets have not been achieved in these countries, they are moving forward in the right direction.

5. The 111 countries that entered the decade with high immunization coverage and sustained it through 2015 are already setting their sights on more aggressive goals, additional vaccines, and more equitable coverage. Immunization programmes in these countries can lead the way by increasing access to other public health interventions and providing a platform for the delivery of preventive health services throughout the life course. Vaccine research and development is progressing rapidly, and an expanding pipeline of new vaccines underscores the need to build health systems that can reliably reach new target age groups.

6. The members of the SAGE are steadfast and passionate believers in the power of immunization to give individuals and their families a better start in life and to protect people from a growing array of debilitating illnesses. Immunization is one of the world’s most effective and cost-effective tools against the threat of emerging diseases and has a powerful impact on social and economic development. Recognizing the role that immunization plays in ensuring good health and the role that good health plays in achieving sustainable development, the SAGE has supported the inclusion of immunization indicators to measure progress toward the Sustainable Development Goals.

7. The next four years present unprecedented opportunities for countries to leverage the attention and support that immunization receives and apply it for the benefit of people everywhere. Strident efforts on the part of all countries and immunization stakeholders are required to catch up and achieve GVAP goals by 2020…

[1]http://www.who.int/entity/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_ Report_2016_EN.pdf (accessed 10 November 2016).

:::::::

Emergencies

Emergencies

Millions of children to receive measles vaccine in north-eastern Nigeria
12 January 2017 – A mass vaccination campaign to protect more than 4 million children against a measles outbreak in conflict-affected states in north-eastern Nigeria is planned to start this week. The two-week campaign, which starts on 13 January, will target all children aged from 6 months to 10 years in accessible areas in Borno, Yobe and Adamawa States.

“This measles vaccination campaign is an emergency intervention to protect more than 4 million children against a highly contagious and sometimes deadly disease,” says Dr Wondimagegnehu Alemu, WHO Representative in Nigeria. “Massive disruption to health services in conflict-affected areas for many years has deprived these children of essential childhood vaccinations. In addition, many of them have severe malnutrition, making them extremely vulnerable to serious complications and death from measles.”

Polio programme provides crucial support
WHO is supporting the 3 state Primary Healthcare Development Agencies to prepare for the campaign; working with partners including UNICEF, the United States Centers for Disease Control (CDC) and other health nongovernmental organizations. WHO is providing expertise in areas including logistics, data management, training, social mobilization, monitoring and evaluation, supportive supervision (human resource) and waste management.

“Nigeria’s well-established polio vaccination programme provides a strong underpinning for the campaign,” says Dr Alemu. “Population data from the polio programme has been essential to guide planning for the measles campaign. We are also able to make use of staff that have vast experience in providing health services in very difficult and risky areas.”

High insecurity, difficult terrain and lack of functioning health facilities add to the enormous logistical challenges of organizing a large mass vaccination campaign that requires assembling and training more than 4000 vaccination teams and ensuring the vaccine is kept within cold chain conditions (+2⁰ to 8⁰ C) in a climate where average daytime temperatures are above 30⁰ C.

The vaccination teams for this campaign are made up of 7 people including a supervisor, vaccinators (health workers), record keepers, community mobilizers and town criers. The teams will also give children deworming medication and vitamin A supplements at the same time as the measles vaccination.

To prevent double vaccinations especially in schools and camps for displaced people, vaccination cards will be issued to all vaccinated children as well as the use of pen markers to mark their thumbs…

:::::::

WHO Grade 3 Emergencies [to 14 January 2017]

The Syrian Arab Republic
:: Survey raises concerns about hepatitis C infection in Syria
10 January 2017 – A survey of more than 20 000 people in Syria has found a concerning number of people infected with hepatitis C, especially among people who are at higher risk.

IraqNo new announcements identified.
South SudanNo new announcements identified.
NigeriaSee measles immunization campaign announcement above.
YemenNo new announcements identified.

WHO Grade 2 Emergencies [to 14 January 2017]

CameroonNo new announcements identified.
Central African RepublicNo new announcements identified.
Democratic Republic of the CongoNo new announcements identified.
Ethiopia No new announcements identified.
LibyaNo new announcements identified.
Myanmar No new announcements identified.
Niger No new announcements identified.
UkraineNo new announcements identified.

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.

Iraq
:: Iraq: Mosul Humanitarian Response Situation Report #15 (2 – 8 January 2017) [EN/AR/KU]

Syria
:: 14 Jan 2017 Syrian Arab Republic: Wadi Barada Situation Report No. 1 (14 January 2017)

Yemen
:: 9 Jan 2017 Yemen Humanitarian Bulletin Issue 19 (31 December 2016)

Corporate Emergencies
Haiti
:: Haiti: Hurricane Matthew – Situation Report No. 31 (09 January 2017)
… 807,395 Individuals living in high-risk areas, including the hurricane zone, received cholera vaccine Source: UNICEF

::::::

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO pages for updates and key developments. No new digest content identified for this edition.

Yellow Fever [to 14 January 2017]

Yellow Fever [to 14 January 2017]
http://www.who.int/emergencies/yellow-fever/en/

Disease Outbreal News [DONs}
Yellow fever – Brazil
13 January 2017
On 6 January 2017, the Brazil Ministry of Health (MoH) reported 12 suspected cases of yellow fever from six municipalities in the state of Minas Gerais…
On 12 January, the Brazil IHR NFP provided an update on the event informing that a total of 110 suspected cases, including 30 deaths, had been reported from 15 municipalities of Minas Gerais…

Public Health Response
Health authorities at the federal, state, and municipal levels are implementing several measures to respond to the outbreak:
:: The Ministry of Health has deployed technical teams to the state of Minas Gerais to assist the state and municipal secretary of health with surveillance and outbreak investigation, vector control, and coordination of health care services;
:: A house-to-house immunization campaign is being conducted in the rural areas of affected municipalities;
:: Preparedness activities are being conducted in states bordering Minas Gerais, for a potential introduction of yellow fever;
:: The local press is working together with the MoH to keep the public constantly informed on the situation.

WHO Risk Assessment
Yellow fever outbreak has previously been detected in Minas Gerais. The most recent outbreak occurred in 2002–2003, when 63 confirmed cases, including 23 deaths (CFR: 37%), were detected.
The current yellow fever outbreak is taking place in an area with relatively low vaccination coverage, which could favor the rapid spread of the disease…

Zika virus [to 14 January 2017]

Zika virus [to 14 January 2017]
http://www.who.int/emergencies/zika-virus/en/

Zika situation report – 05 January 2017
Full report: http://apps.who.int/iris/bitstream/10665/252762/1/zikasitrep5Jan17-eng.pdf?ua=1
Key Updates
:: This is the last weekly situation report. Going forward, the reports will be published every two weeks. The next report will be issued on 19 January.

WHO’s response to Zika virus and its associated complicationsReport to donors: December 2016
WHO, 2016 :: 11 pages
[Excerpt]
On 1 February 2016 WHO Director-General Margaret Chan declared that the spread of Zika virus and its associated complications constituted a public health emergency of international concern (PHEIC). On 14 February, WHO launched a global Strategic Response Framework and Joint Operations Plan, subsequently updated on 15 July, in which WHO and partners set out their strategy for preventing, detecting, and responding to Zika virus and its complications. Support from donors has ensured that this strategy has been realised.
Between February and November 2016 WHO/PAHO received US$ 23.9 million in direct contributions from 13 donors (Annex 1). This document highlights some of WHO’s key activities during this period, and points to priority areas for funding through to December 2017, including investment in research and development to foster a better understanding of Zika virus epidemiology, and how we can prevent and treat the adverse health outcomes associated with Zika virus infection.
The figure below shows how funds were received over time to pay for the response outlined in the Zika Strategic Response Plan. Funds from the WHO Contingency Fund for Emergencies (CFE) were disbursed within 24 hours of the declaration of the PHEIC, and were crucial in the early stages of the response, enabling a full Incident Management Structure (IMS) to be implemented in WHO headquarters in Geneva and all WHO regional offices. Without this bridge funding the response would have been delayed until the first contributions from Japan and Australia were received, 6 weeks after the declaration of the PHEIC. Eleven months after the declaration of the PHEIC, and thanks to the generosity of donors, funding has been secured..

::::::

POLIO [to 14 January 2017]

POLIO [to 14 January 2017]
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 11 January 2017
:: Summary of newly-reported viruses this week (see country-specific section below for further details): Pakistan: one circulating vaccine-derived poliovirus type 2 (cVDPV2) isolated from an acute flaccid paralysis (AFP) case; three positive environmental samples (two wild poliovirus type 1 – WPV1, and one cVDPV2).

Country Updates [Selected Excerpts]
Pakistan
:: Two new WPV1-positive environmental samples were reported in the past week, from Multan, Punjab (collected on 8 December) and Karachi-Landhi (greater Karachi), Sindh (collected on 14 December).
:: One new circulating vaccine-derived poliovirus type 2 (cVDPV2) case was reported in the past week, from Quetta, Balochistan, with onset of paralysis on 17 December.
:: One new cVDPV2-positive environmental sample was reported in the past week, from Quetta (collected on 20 December).
:: The isolates from both the cVDPV2 case and environmental sample are linked to an ongoing, confirmed cVDPV2 outbreak currently affecting Quetta. The case is the first associated with this outbreak – previous isolates of this strain had been found only in environmental samples.
:: An outbreak response is currently ongoing. Last week, a campaign using monovalent oral polio vaccine type 2 (mOPV2) was implemented in Quetta and surrounding areas, followed this week by an activity with inactivated polio vaccine (IPV). The Ministry of Health, supported by the World Health Organization (WHO) and partners, is further strengthening active search for cases of acute flaccid paralysis (AFP), and conducting an in-depth field investigation to more clearly ascertain the extent of circulation of the cVDPV2.

::::::

WHO & Regional Offices

WHO & Regional Offices [to 14 January 2017]

140th session of the Executive Board
23 January–1 February 2017, Geneva
[see selected main documents summary above]

Tobacco control can save billions of dollars and millions of lives
10 January 2017 – Policies to control tobacco use, including tobacco tax and price increases, can generate significant government revenues for health and development work, according to a new landmark global report from WHO and the National Cancer Institute of the United States of America.

Highlights
Dracunculiasis eradication: Mali reports zero cases in 2016
January 2017 – In 2016, a total of 25 human cases of dracunculiasis (guinea-worm disease) were reported to WHO; Mali reported zero cases for the first time. In 2015, Mali reported 5 human cases.

Consultation: Global Accelerated Action for the Health of Adolescents (AA-HA!) Implementation Guidance Draft
January 2017 – The first draft of the Global AA-HA! Implementation Guidance is now available for review by individuals and institutions. If you have feedback, please respond by 15th January 2017 so that your comments can influence and be incorporated into the final document.

Response to trauma cases saves hundreds of lives in Iraq
January 2017 – Since 17 October 2016, WHO has supported the Government of Iraq and the Kurdish Regional Government with emergency lifesaving health services, including emergency medicines and other medical supplies like trauma and surgery kits.

Weekly Epidemiological Record, 13 January 2017, vol. 92, 2 (pp. 13–20)
Global Advisory Committee on Vaccine Safety, 30 November – 1 December 2016

:: WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
:: Millions of children to receive measles vaccine in north-eastern Nigeria
A mass vaccination campaign to protect more than 4 million children (4 766 214) against a measles outbreak in conflict-affected states in north-eastern Nigeria is planned to start this week.

WHO Region of the Americas PAHO
:: Tobacco control can save billions of dollars and millions of lives (01/10/2017)

WHO South-East Asia Region SEARO
:: Countries in South-East Asia Region combat polio vaccine shortage, committed to remain polio-free 13 January 2017
On the sixth anniversary of the last case of wild poliovirus in the South-East Asia Region, World Health Organization commends countries in the Region for their continued efforts to protect children against this crippling virus and maintain the Region’s polio-free status, despite challenging conditions.
Amid a global shortage of injectable inactivated polio vaccine (IPV), countries in the WHO South-East Asia Region are opting to use fractional doses of IPV, an evidence-based intervention that not only ensures continued protection of children against all types of polioviruses, but also helps save vaccine – a move bound to positively impact global vaccine supply in the coming years.
India became the first country globally to introduce fractional doses of IPV in childhood immunization programme in eight of its 36 states / union territories in early 2016. The initiative is now being scaled up nationwide. Sri Lanka followed suit in July 2016. Bangladesh has decided to introduce fractional IPV doses this year. Other countries in the Region are also considering a shift to the use of fractional IPV doses in their immunization schedule…

WHO European Region EURO
:: Kick-off meeting of UN European coalition on health identifies 4 workstreams for joint action 13-01-2017
:: What can countries expect during the 2016–2017 influenza season? 13-01-2017

WHO Eastern Mediterranean Region EMRO
:: Survey raises concerns about hepatitis C infection in Syria 10 January 2017

WHO Western Pacific Region
:: Tobacco control can save billions of dollars and millions of lives 10 JANUARY 2017

::::::

CDC/ACIP [to 14 January 2017]

CDC/ACIP [to 14 January 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/

MMWR Weekly January 13, 2017/No. 1
[Excerpts]
:: State Laws Requiring Hand Sanitation Stations at Animal Contact Exhibits—United States, March–April 2016
:: Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States

Register for upcoming February ACIP meeting
February 22-23, 2017
Deadline for registration:
:: Non-US Citizens: February 1, 2017; US Citizens: February 13, 2017
Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Announcements

Announcements

IVI [to 14 January 2017]
http://www.ivi.int/

[Undated]
IVI, Rotary International Join Forces to Vaccinate against Cholera in At-risk Populations in Nepal
:: Campaign to vaccinate about 27,000 people to prevent endemic cholera
:: IVI Director General commends Rotary’s leadership and support, announces intent to provide additional vaccinations in developing countries through international collaboration

The International Vaccine Institute (IVI), Rotary International (District 3640, District 3710), Rotary Club of Seoul Southwest in Korea, and Rotary Club of Nagarjun in Nepal announced on January 9 their global health partnership that recently completed vaccination of about 27,000 people at risk of cholera in Nepal.

The vaccinations have been conducted in Banke, an area in southwest Nepal that borders with India, to protect people against cholera, a potentially fatal and highly contagious diarrheal disease. Cholera is endemic in Nepal, and people in the area are at high risk of cholera due to lack of clean water and limited sanitation and hygiene.

The vaccination campaign used a two-dose oral cholera vaccine, developed by IVI through a public-private partnership with groups that include the Bill & Melinda Gates Foundation and the governments of Korea and Sweden. Notably, the vaccine ‘Euvichol’ is produced by the Korean vaccine manufacturer EuBiologics who worked with IVI on its development and production following technology transfer from IVI. The vaccine is prequalified by the World Health Organization and is the first Korean-made cholera vaccine for global public health.

To ensure the vaccine reaches vulnerable populations, IVI collaborated with Rotary International and Nepalese health authorities to conduct the vaccination campaign, targeting residents one year old and up.  The first round occurred on early December, and the second round in mid- to late December.

The vaccination campaign was led by Rotary Club of Seoul Southwest and International Rotary Districts 3640 and 3710, and was supported through a Global Grant from the Rotary Foundation. Collaborators in Nepal included the Nepalese Ministry of Health, Group for Technical Assistance (GTA), and other partners. The campaign was also supported by a number of Korean donors, including the Export Import Bank of Korea, the Kim & Chang CSR Committee, and Sartorius Korea Biotech…

PATH [to 14 January 2017]

PATH [to 14 January 2017]
http://www.path.org/news/index.php

Announcement | January 12, 2017
PATH welcomes grant to advance Group B Streptococcus vaccine development
Award from the Bill & Melinda Gates Foundation will support maternal immunization strategies
PATH has received a five-year, $29.3 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against Group B Streptococcus (GBS), a leading cause of sepsis and meningitis in young infants worldwide. A vaccine to prevent the bacterial infection—which often affects babies just a few hours old—could potentially save countless lives in the low-resource countries most impacted by the disease. Grant funds will support the research and development of a polyvalent, conjugate vaccine protecting against the most common kinds (or serotypes) of GBS…

European Medicines Agency [to 14 January 2017]

European Medicines Agency [to 14 January 2017]
http://www.ema.europa.eu/
13/01/2017

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 January 2017
At its monthly meeting, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed two ongoing safety reviews.
More information on all safety reviews currently under evaluation is provided in the table below. The Committee did not start or conclude a referral.
The PRAC also focused on the broad range of its responsibilities which cover all aspects of the risk management of the use of medicines. Information on all topics discussed by the PRAC is available below in the agenda for the meeting. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next PRAC meeting at the beginning of February…

European Vaccine Initiative [to 14 January 2017]

European Vaccine Initiative [to 14 January 2017]
http://www.euvaccine.eu/news-events
09 January 2017

EVI welcomes a new member to the team
EVI extends a warm welcome to María del Mar Castro. Ms del Mar Castro joins EVI with a fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). She began her one-year Clinical Research and Development fellowship on 09 January 2017.

09 January 2017
A new paper related to the MVVC project has recently been published in Molecular Therapy
The article “Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants” was published by Carly Bliss et al. in Molecular Therapy.

::::::

Industry Watch [to 14 January 2017]

Industry Watch [to 14 January 2017]
:: Joaquin Duato Named PhRMA Board Chairman
Washington, DC (January 9, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, has been named chairman of PhRMA’s board of directors. Duato formerly held the position of chairman-elect of the PhRMA board and succeeds George Scangos, who has stepped down as CEO of Biogen…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Tropical Medicine and Hygiene – January 2017; 96 (1)

American Journal of Tropical Medicine and Hygiene
January 2017; 96 (1)
http://www.ajtmh.org/content/current

Editorials
Evidence-Based Policies on Migration and Global Health are Essential to Maintain the Health of Those Inside and Outside the United States
Philip J. Rosenthal, Daniel G. Bausch, Stephen Higgs, N. Regina Rabinovich, David R. Hill, Christopher V. Plowe, Karen A. Goraleski, and Patricia F. Walker
Am J Trop Med Hyg 2017 96:5-6; doi:10.4269/ajtmh.961ed

Excerpt
…In addition to maintaining a humane and evidence-based U.S. policy on migration, we must continue to engage and invest in programs that improve the health of vulnerable populations worldwide. Reaching out to enhance the well-being of those whose lives has been torn apart by war and oppression should be a fundamental and perhaps defining American principle. Programs for populations in need around the world should not be considered antiquated historical notions or reflective of an outmoded inscription on the Statue of Liberty. Indeed, U.S. government leaders from both sides of the political aisle have championed programs aimed at global health, including the creation of the Peace Corps by President John F. Kennedy in 1961, and the President’s Emergency Plan for AIDS Relief and President’s Malaria Initiative by President George W. Bush in 2003 and 2005, respectively. Additional efforts have been shared with other developed countries, notably the Global Fund to Fight AIDS, Tuberculosis, and Malaria. These well-managed programs have offered enormous benefits to the citizens of the developing world, but they have also directly benefitted the United States, by helping to control some of the most important infectious diseases that threaten all of us, by building diplomatic bridges of good will with populations around the world, and by exemplifying the best of American values of kindness and compassion…

BMC Infectious Diseases

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 14 January 2017)

Research article
Mumps transmission in social networks: a cohort study
Mumps emerged among highly vaccinated populations in the Netherlands. This offered a unique opportunity to study mumps virus transmission. In particular the extent to which asymptomatic infections in vaccinate…
Susan Hahné, Tessa Schurink, Jacco Wallinga, Jeroen Kerkhof, Marianne van der Sande, Rob van Binnendijk and Hester de Melker
BMC Infectious Diseases 2017 17:56
Published on: 10 January 2017

Research article
Seasonal influenza vaccination in pregnant women: knowledge, attitudes, and behaviors in Italy
The aims of this study were to assess the knowledge, attitudes, and behaviors towards seasonal influenza and its vaccination among pregnant women.
Francesco Napolitano, Paola Napolitano and Italo Francesco Angelillo
BMC Infectious Diseases 2017 17:48
Published on: 9 January 2017

BMC Public Health

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 14 January 2017)

Research article
An audit of the quality of online immunisation information available to Australian parents
The Internet is increasingly a source of health information for parents, who use the Internet alongside health care providers for immunisation information. Concerns have been raised about the reliability of on…
K. E. Wiley, M. Steffens, N. Berry and J. Leask
BMC Public Health 2017 17:76
Published on: 13 January 2017

The European Journal of Public Health – Volume 26, Issue 6, 1 December 2016

The European Journal of Public Health
Volume 26, Issue 6, 1 December 2016
http://eurpub.oxfordjournals.org/content/26/6

Editorials
Lonely and bored stiff: challenging phase for ethnic minority and migrant health in Europe Restricted Access
Charles Agyemang Eur J Public Health (2016) 26 (6): 898-899 DOI: http://dx.doi.org/10.1093/eurpub/ckw112 First published online: 13 October 2016 (2 pages)

Viewpoint
Environmental and public health tracking to advance knowledge for planetary health
Behrooz Behbod, Paolo Lauriola, Giovanni Leonardi, Helen Crabbe, Rebecca Close, Brigit Staatsen, Lisbeth E. Knudsen, Kees de Hoogh, Sylvia Medina, Jan C. Semenza, Tony Fletcher Eur J Public Health (2016) 26 (6): 900 DOI: http://dx.doi.org/10.1093/eurpub/ckw176 First published online: 15 October 2016 (1 pages)

Infectious Diseases of Poverty

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 14 January 2017]

Research Article
Domestic trends in malaria research and development in China and its global influence
Yang-Mu Huang, Lu-Wen Shi, Rui She, Jing Bai, Shi-Yong Jiao and Yan Guo
Published on: 10 January 2017
Abstract
Background
Though many countries, including China, are moving towards malaria elimination, malaria remains a major global health threat. Due to the spread of antimalarial drug resistance and the need for innovative medical products during the elimination phase, further research and development (R&D) of innovative tools in both epidemic and elimination areas is needed. This study aims to identify the trends and gaps in malaria R&D in China, and aims to offer suggestions on how China can be more effectively involved in global malaria R&D.
Methods
Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes between 1985 and 2014, invention patents in China from 1985 to 2014, and articles published by Chinese researchers in PubMed and Chinese databases from 2005 to 2014. All data were screened and extracted for numerical analysis and were categorized into basic sciences, drug/drug resistance, immunology/vaccines, or diagnostics/detection for chronological and subgroup comparisons.
Results
The number of malaria R&D activities have shown a trend of increase during the past 30 years, however these activities have fluctuated within the past few years. During the past 10 years, R&D on drug/drug resistance accounted for the highest percentages of research programmes (32.4%), articles (55.0% in PubMed and 50.6% in Chinese databases) and patents (45.5%). However, these R&D activities were mainly related to artemisinin. R&D on immunology/vaccines has been a continuous interest for China’s public entities, but the focus remains on basic science. R&D in the area of high-efficiency diagnostics has been rarely seen or reported in China.
Conclusions
China has long been devoted to malaria R&D in multiple areas, including drugs, drug resistance, immunology and vaccines. R&D on diagnostics has received significantly less attention, however, it should also be an area where China can make a contribution. More focus on malaria R&D is needed, especially in the area of diagnostics, if China would like to contribute in a more significant way to global malaria control and elimination.

JAMA – January 10, 2017, Vol 317, No. 2, Pages 103-222

JAMA
January 10, 2017, Vol 317, No. 2, Pages 103-222
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans
Johannes J. M. van Delden, MD, PhD; Rieke van der Graaf, PhD
JAMA. 2017;317(2):135-136. doi:10.1001/jama.2016.18977
Abstract
The Council for International Organizations of Medical Sciences (CIOMS) was established jointly by the World Health Organization (WHO) and the United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as an international, nongovernmental, nonprofit organization and now includes 45 international, national, and associate member organizations, representing many of the biomedical disciplines, national academies of sciences, and medical research councils. CIOMS recently released a new version of its International Ethical Guidelines for Health-Related Research Involving Humans. These guidelines were developed in collaboration with WHO and based on authoritative ethical guidance documents, such as the World Medical Association’s Declaration of Helsinki and UNESCO’s Universal Declaration on Bioethics and Human Rights. The aim of the guidelines is to provide internationally vetted ethical principles and detailed commentary on how these principles should be applied, with particular attention to conducting research in low- and middle-income countries (LMICs).

Journal of Travel Medicine – Volume 24, Issue 1, January 2017

Journal of Travel Medicine
Volume 24, Issue 1, January 2017
http://jtm.oxfordjournals.org/content/24/1

Original Article
Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries
Anita E. Heywood, Hans Nothdurft, Dominique Tessier, Melissa Moodley, Lars Rombo, Cinzia Marano, Laurence De Moerlooze J Travel Med (2017) 24 (1): taw069 DOI: http://dx.doi.org/10.1093/jtm/taw069 First published online: 13 October 2016 (8 pages)

Editor’s Choice
Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet
Sara M. Lammert, Sowmya R. Rao, Emily S. Jentes, Jessica K. Fairley, Stefanie Erskine, Allison T. Walker, Stefan H. Hagmann, Mark J. Sotir, Edward T. Ryan, Regina C. LaRocque J Travel Med (2017) 24 (1): taw075 DOI: http://dx.doi.org/10.1093/jtm/taw075 First published online: 30 October 2016 (7 pages)

Journal of Virology – January 2017, volume 91, issue 2

Journal of Virology
January 2017, volume 91, issue 2
http://jvi.asm.org/content/current

Vaccines and Antiviral Agents
One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus
Christoph Wirblich, Christopher M. Coleman, Drishya Kurup, Tara S. Abraham, John G. Bernbaum, Peter B. Jahrling, Lisa E. Hensley, Reed F. Johnson, Matthew B. Frieman, and Matthias J. Schnell
J. Virol. January 2017 91:e02040-16; Accepted manuscript posted online 2 November 2016 , doi:10.1128/JVI.02040-16
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G–MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.
IMPORTANCE Rabies virus-based vectors have been proven to be efficient dual vaccines against rabies and emergent infectious diseases such as Ebola virus. Here we show that inactivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses against MERS-CoV and RABV. This novel vaccine is easy to produce and may be useful to protect target animals, such as camels, as well as humans from deadly MERS-CoV and RABV infections. Our results indicate that this vaccine approach can prevent disease, and the RABV-based vaccine platform may be a valuable tool for timely vaccine development against emerging infectious diseases.

The Milbank Quarterly A Multidisciplinary Journal of Population Health and Health Policy December 2016 Volume 94, Issue 4 Pages 695–928

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
December 2016 Volume 94, Issue 4 Pages 695–928
http://onlinelibrary.wiley.com/doi/10.1111/milq.2016.94.issue-4/issuetoc

Op-Eds
A Very Long Journey: A Decade’s Quest for Quarantine Regulations (pages 724–728)
LAWRENCE O. GOSTIN
Version of Record online: 19 DEC 2016 | DOI: 10.1111/1468-0009.12226

Review Article
Instruments Measuring Integrated Care: A Systematic Review of Measurement Properties (pages 862–917)
MARY ANN C. BAUTISTA, MILAWATY NURJONO, YEE WEI LIM, EZRA DESSERS and HUBERTUS JM VRIJHOEF
Version of Record online: 19 DEC 2016 | DOI: 10.1111/1468-0009.12233
Abstract
Policy Points:
:: Investigations on systematic methodologies for measuring integrated care should coincide with the growing interest in this field of research.
:: A systematic review of instruments provides insights into integrated care measurement, including setting the research agenda for validating available instruments and informing the decision to develop new ones.
:: This study is the first systematic review of instruments measuring integrated care with an evidence synthesis of the measurement properties.
:: We found 209 index instruments measuring different constructs related to integrated care; the strength of evidence on the adequacy of the majority of their measurement properties remained largely unassessed

New England Journal of Medicine – January 12, 2017  Vol. 376 No. 2

New England Journal of Medicine
January 12, 2017  Vol. 376 No. 2
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Eliminating Cholera Transmission in Haiti
Louise C. Ivers, M.D., M.P.H.
N Engl J Med 2017; 376:101-103 January 12, 2017 DOI: 10.1056/NEJMp1614104
Interview with Dr. Louise Ivers on cholera transmission and vaccination efforts in post-hurricane Haiti. (6:48) Listen Download
When Hurricane Matthew struck on October 4, 2016, it left 1.4 million people in southern Haiti in need of urgent humanitarian assistance; it destroyed homes and health care facilities, flooded water sources with runoff, ruined crops, killed livestock, and displaced hundreds of thousands of people. Looming as the next act in the disaster is a resurgence in endemic cholera.

Cholera had not been recorded in Haiti until it was introduced in 2010. The introduction of Vibrio cholerae into a population that had never been exposed to cholera and that had extremely limited access to safe water and sanitation had a predictable effect: an explosive cholera epidemic that has killed at least 10,000 people and caused nearly 800,000 reported cases throughout the country.1

Now in its seventh year, the epidemic has taken an immeasurable toll on individuals, communities, and the health system in Haiti, and the resources for controlling it have been too limited. In 2015, Haiti reported more cases of cholera per population than any other country. In 2016, there were 29,000 cases of cholera in the first 9 months of the year — already a disaster before the hurricane hit. And as is so often the case, the poor have suffered the most. New approaches are needed to address the ongoing problem and mitigate suffering from cholera in Haiti. The hurricane’s aftermath adds urgency to this problem.

On October 13 and 14, 2016, the minister of health and population of Haiti, Daphnee Benoit, convened an expert panel at the U.S. National Institutes of Health to consult on the control of cholera in Haiti with specific reference to the use of vaccines in the aftermath of Hurricane Matthew. Two weeks after Hurricane Matthew, the number of cholera cases had grown, and many were concerned about the impact on human life. The consultation resulted in the following consensus.

The response to Hurricane Matthew must first and foremost address the victims’ need for humanitarian relief, through provision of food, shelter, and clean water to those who lack these lifesaving essentials. Rallying emergency clean-water activities to combat the known risk of cholera in the immediate phase is an important strategy. We should assume, at least initially, that there has been further contamination of freshwater sources in Haiti’s southern peninsula. Ensuring that people have access to and use effectively chlorinated water, with safe water storage at home (or in shelters), is a critical lifesaving objective.

There is a simultaneous need to ensure that cholera treatment centers and oral rehydration posts are functional. After the hurricane, many of these facilities will have to be rebuilt; resupplied with rehydration fluids, antibiotics, and zinc for children; and supported with staff to perform effective case finding in the community and rapid treatment of the sick. These strategies have not changed since the beginning of the cholera epidemic in 2010, although in recent years resources to implement them have dwindled.

When the cholera epidemic began in Haiti, and for some years afterward, there was a lack of consensus on the role that oral cholera vaccine (OCV) could play in the response. One clear issue, however, was that the supply of vaccine was very limited, and there was limited experience in using OCVs in response to outbreaks. Furthermore, the fact that the most affordable vaccine had not yet met prequalification requirements of the World Health Organization (WHO) meant that the United Nations Children’s Fund (UNICEF) and other United Nations agencies could not purchase it.

Since that time, a number of developments have enhanced our ability to control the epidemic in Haiti. Two safe, effective OCVs are now available at an affordable cost ($1.70 to $1.85 per dose), are prequalified by the WHO, and are available in increasing quantities. The products are essentially the same vaccine, made by different manufacturers. Shanchol (Shantha Biotechnics, India) was prequalified in 2011. In 2013, a 2-million-dose OCV stockpile was established as a public good to manage the vaccine. Euvichol (Eubiologics, South Korea) was prequalified by the WHO in 2015, and the manufacturer recently announced that it could produce 25 million single-dose vials per year that remain stable at 37°C for 30 days, avoiding waste and enabling delivery to the most remote areas without requiring a stringent cold chain. Other OCVs are available (VaxChora, PaxVax, United States; Dukoral, Valneva, Sweden) but at this time are not considered practical for major public health use in resource-poor settings.

Finally, a series of studies with OCVs in Haiti have demonstrated the efficacy of the Shanchol vaccine in both urban and rural settings, the feasibility of achieving high coverage rates, and the low cost of delivering this vaccine to the population. In one of the poorest urban slums of Haiti, not a single case of culture-confirmed cholera occurred between September 2013 and August 2016 in persons who had received a combined intervention ensuring household chlorination and cholera vaccination.2-4 This research complements other recent OCV studies from Guinea and South Sudan.

This information fundamentally changes the way health authorities should now consider the use of OCV in controlling cholera. Mass vaccination in Haiti would save lives, and modeling suggests that such an intervention, coupled with targeted, effective water, sanitation, and hygiene interventions, could substantially control, if not eliminate, the disease within a few years of the program’s introduction, at an affordable cost. This medium-term plan will have to be undertaken in concert with a long-term effort to realize the human right of access to clean water, a goal that will require a substantial budget and years, if not decades, to accomplish.

Control of cholera was a problem in Haiti for the 6 years before Hurricane Matthew — not only because there were insufficient resources, but also owing to the enormity of the challenge of redressing the population’s severely constrained access to clean water and sanitation.
One million doses of OCV were requested by the Haitian Ministry of Public Health and Population and authorized as part of the emergency response to Hurricane Matthew.5 Two shipments of 500,000 doses arrived in Haiti on October 24 and 25, 2016, and the vaccines have been deployed by the Ministry of Health and its partners for urgent use. We of the Special Consulting Group to the Minister of Health and Population of Haiti commend the mass-vaccination approach in the hurricane-affected areas of the south of Haiti as one part of a comprehensive emergency response. In light of recent data on vaccine efficacy, the feasibility of vaccinating in outbreak settings, and the increased availability of safe, effective, and low-cost vaccines, we urge, in addition to an emergency response to cholera in the hurricane-affected communities, that intense and reinvigorated support be provided to the government’s National Plan for the Elimination of Cholera in Haiti, including a nationwide two-dose oral cholera vaccination campaign.

Over the past six decades, several public health programs in Haiti (e.g., those focused on HIV care and treatment and control of neglected tropical diseases) have provided models for the world. The increased availability of OCVs and their rollout in a national program could provide an opportunity for the government of Haiti and the international community to demonstrate another successful strategy: comprehensive national OCV coverage combined with targeted water, sanitation, and hygiene interventions could eliminate the transmission of cholera in Haiti over the next 3 to 5 years at an affordable cost (some estimates suggest approximately $66 million). This goal is surely one to aspire to, given the human cost of maintaining the status quo.

Eliminating cholera transmission in Haiti with a combined, integrated approach at the population level would be a major achievement for the government and people of Haiti. It would also have broad implications for the control of cholera in other affected populations around the world. The time for ambitious action on cholera control and elimination in Haiti is now.

PLOS Currents: Disasters

PLOS Currents: Disasters
http://currents.plos.org/disasters/
[Accessed 14 January 2017]

Discussion
The Politics of Global Public Health in Fragile States and Ungoverned Territories
January 9, 2017 ·
The reasons for global health crises and how the world responds to them have dramatically changed over the last half century. Increasingly, natural disasters result in failure of public health and security systems leading to preventable conflict, unconventional war and unprecedented population migration. While scientific expertise exists to mitigate these failures in fragile states and ungoverned territories, inactions are mired by the lack of political will, international legal mandates, and capacity to strategically monitor multidisciplinary public health indicator failures.

PLoS Currents: Outbreaks

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 14 January 2017]

Research Article
Strategic Interactions in Antiviral Drug Use During an Influenza Pandemic
January 12, 2017
Background: The evolution of antiviral drug resistance during influenza pandemics has created widespread concern. Use of antiviral drugs is a main contributor to the evolution of drug-resistant strains. Moreover, there are recent examples of influenza viruses acquiring drug resistance seemingly without incurring a fitness penalty that reduces their transmission rate. This creates the possibility of strategic (game theoretical) interaction between jurisdictions making decisions about use of antiviral drug stockpiles.
Methods: We developed and analyzed a 2-player 2-strategy game theoretical model. Each ‘player’ (an authority in a health jurisdiction) can choose to treat with antiviral drugs at a low rate or a high rate. High treatment rates are more likely to cause emergence of a drug-resistant strain, and once a drug-resistant strain has evolved, it can spread between the two jurisdictions. We determine the Nash equilibria of the game.
Results: We show that there is a coordination game between the jurisdictions, where both players choosing a low treatment rate, or both choosing a high treatment rate, are the only stable outcomes. The socially optimal outcome occurs if both players cooperate by choosing a low treatment rate, thereby avoiding generating drug-resistant mutants. However, such cooperation may fail to materialize if the jurisdictions are closely connected through travel; if the drug-resistant mutant is tolerated (not seen as undesirable); or if the antiviral drug has partial efficacy against transmission of the drug-resistant strain.
Conclusions: Inter-jurisdictional cooperation could be essential during a severe influenza pandemic, but we know little about how jurisdictions will interact in a scenario where highly pathogenic, drug-resistant mutant strains are able to transmit as effectively as non-resistant strains. Therefore, strategic multi-population interactions during influenza pandemics should be further studied.

PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 14 January 2017)

Research Article
Forecasting Zika Incidence in the 2016 Latin America Outbreak Combining Traditional Disease Surveillance with Search, Social Media, and News Report Data
Sarah F. McGough, John S. Brownstein, Jared B. Hawkins, Mauricio Santillana
| published 13 Jan 2017 PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0005295

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 14 January 2017]

Research Article
Decreasing Seroprevalence of Measles Antibodies after Vaccination – Possible Gap in Measles Protection in Adults in the Czech Republic
Jan Smetana, Roman Chlibek, Irena Hanovcova, Renata Sosovickova, Libuse Smetanova, Peter Gal, Petr Dite
Research Article | published 13 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0170257

Research Article
Racial and Ethnic Disparities in Influenza Vaccination among Adults with Chronic Medical Conditions Vary by Age in the United States
Degan Lu, Yanru Qiao, Natalie E. Brown, Junling Wang
Research Article | published 12 Jan 2017 PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0169679

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
Recently Published Articles –
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101

Special Issue on HIV/AIDS in the Americas
Editorial | Published 13 January
What will it take to end AIDS in the Americas?
[¿Qué se necesita para terminar con el sida en la Región de las Américas?]
Carissa F. Etienne

Overview Published 13 January |
HIV/AIDS prevention, care and treatment in the Region of the Americas:
achievements, challenges and perspectives
[Prevención, atención y tratamiento de la infección por el VIH/sida en la Región de
las Américas: logros, retos y perspectivas]
Freddy Pérez, Giovanni Ravasi, J.Peter Figueroa, Beatriz Grinsztejn, Mary Kamb, Omar Sued, and Massimo Ghidinelli

Vaccine – Volume 35, Issue 2, Pages 201-410 (5 January 2017)

Vaccine
Volume 35, Issue 2, Pages 201-410 (5 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/2

Original Research Article

Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand
Original Research Article
Pages 299-304
Tawee Chotpitayasunondh, Pornpimol Pruekprasert, Thanyawee Puthanakit, Chitsanu Pancharoen, Auchara Tangsathapornpong, Peninnah Oberdorfer, Pope Kosalaraksa, Olarn Prommalikit, Suwimon Tangkittithaworn, Phirangkul Kerdpanich, Chonnamet Techasaensiri, Joanna Korejwo, Sunate Chuenkitmongkol, Guy Houillon
Abstract
Background
Japanese encephalitis is a mosquito-borne viral disease endemic in most countries in Asia. A recombinant live, attenuated Japanese encephalitis virus vaccine, JE-CV, is licensed in 14 countries, including Thailand, for the prevention of Japanese encephalitis in adults and children.
Methods
This was a prospective, phase IV, open-label, multicentre, safety study of JE-CV conducted from November 2013 to April 2015, to evaluate rare serious adverse events (AEs). JE-CV was administered to 10,000 healthy children aged 9 months to Results
The median age of participants was 1.1 years in Group 1 and 3.8 years in Group 2. SAEs were reported in 204 (3.0%) participants in Group 1 and 59 (1.9%) participants in Group 2. Among a total of 294 SAEs in 263 participants, only three events occurring in two participants were considered related to vaccination. All three cases were moderate urticaria, none of which met the definition of AEs of special interest for hypersensitivity. AEs of special interest were reported in 28 (0.4%) participants in Group 1 and 4 (0.1%) participants in Group 2; none were considered related to vaccination. Febrile convulsion was the most frequently reported AE of special interest: 25 (0.4%) participants in Group 1; and 2 (<0.1%) in Group 2. There were no cases of Japanese encephalitis reported. No Grade 3 immediate systemic AEs were reported after any JE-CV vaccination.
Conclusions
Our study did not identify any new safety concerns with JE-CV and confirms its good safety profile.
This study was registered on http://www.clinicaltrials.gov (NCT01981967; Universal Trial Number: U1111-1127-7052)